News - General

Edmund (Ed) Vanderbeck joins XGen Pharmaceuticals DJB, Inc.

On May 4, 2020, Ed Vanderbeck joined XGen Pharmaceuticals DJB, Inc. as President, becoming only the third person to fill the position since the founding of Pharma-Tek almost 50 years ago.  Ed joins XGen DJB as a proven pharmaceutical industry leader having spent the last twelve years of his career with Chemwerth, Inc., a full [...]

The Release of Folic Acid Injection, USP

XGen Pharmaceuticals DJB, Inc. announced today it will begin marketing and distributing Folic Acid Injection, USP.  Folic Acid Injection, USP is a sterile non pyrogenic solution of sodium folate (prepared by the addition of sodium hydroxide to folic acid) in Water for Injection, USP intended for intramuscular (IM), intravenous (IV) or subcutaneous (SC) use. Folic [...]

The Relaunch of Ibuprofen Lysine

Big Flats NY - XGen Pharmaceuticals DJB Inc. announced today the relaunch of Ibuprofen Lysine injection.  Ibprofen Lysine injection is therapeutically equivalent to Recordati Rare Diseases’ NeoProfen® Injection.Ibuprofen Lysine Injection is indicated to close a clinically significant patent ductus arteriosus (PDA), an abnormal opening between the aorta and the pulmonary artery. Ibuprofen Lysine treats premature infants [...]

XGen Pharmaceuticals DJB, Inc. is closely monitoring the status of the COVID-19 outbreak.

XGen Pharmaceuticals DJB, Inc. is closely monitoring the status of the COVID-19 outbreak and its impact locally and globally. Due to the crucial role we play in providing pharmaceutical products to hospitals, and healthcare facilities throughout the supply chain, we are open and continue to operate with minimal staff to keep products going out to [...]

X-Gen Pharmaceuticals, Inc. becomes XGen Pharmaceuticals DJB, Inc.

X-GEN Pharmaceuticals is excited to announce we are evolving into a new company. Effective January 1, 2020, our new name is XGen Pharmaceuticals DJB, Inc. This change is not the result of a sale or merger of the company but simply a reflection of our growth in the changing pharmaceutical industry. Soon we will be [...]

The Release of Dactinomycin for Injection, USP

Big Flats, NY., August 1st, 2019 – X-GEN Pharmaceuticals announced today the immediate availability in the United States of Dactinomycin for Injection, USP. Dactinomycin is an actinomycin indicated for the treatment of: • adult and pediatric patients with Wilms tumor, as part of a multi-phase, combination chemotherapy regimen. • adult and pediatric patients with rhabdomyosarcoma, [...]

X-GEN Pharmaceuticals Begins Marketing and Distributing Piperacillin and Tazobactam for Injection

Big Flats, NY, March 1, 2017 – X-GEN Pharmaceuticals announced today it will begin marketing and distributing Piperacillin and Tazobactam for Injection. X-GEN’s Piperacillin and Tazobactam for Injection is a combination penicillin-class antibacterial and β-lactamase inhibitor indicated for the treatment of various bacterial infections. The medical community has been plagued by shortages and inconsistencies in [...]

X-GEN Pharmaceuticals receives first generic FDA approval for Lincomycin Injection, USP

Big Flats, NY, February 1, 2016 - X-GEN Pharmaceuticals, Inc. becomes the first generic alternative to receive FDA approval of their ANDA for the marketing and distribution of Lincomycin Injection, USP. Lincomycin is used to treat serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci when penicillin is inappropriate due to patient allergies [...]

X-GEN Pharmaceuticals, Inc. Begins Supplying Magnesium Sulfate

Big Flats, NY, March 2, 2015 - X-GEN Pharmaceuticals announces availability of Magnesium Sulfate Injection, USP. Healthcare systems around the U.S are experiencing a shortage of Magnesium Sulfate, which is a critical component in Total Parenteral Nutrition (TPN), supplying vital nutrients to patients who need IV nutrition to stay alive. It also is indicated as [...]